Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end

AGIOS PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$3.14 revenue$16,804,000

PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.
Net loss $96.1M vs $83.8M YoY; cash, equivalents, marketable securities $645.3M at June 30.
Phase 3 ENERGIZE-T met primary endpoint in transfusion-dependent thalassemia; sNDA filing planned by end of 2024.
Announced $905M purchase agreement with Royalty Pharma for vorasidenib royalty; total $1.1B payable upon FDA approval.
Announced ACTIVATE-KidsT topline data in pediatric PK deficiency; ACTIVATE-Kids enrollment complete, data in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.